<DOC>
	<DOCNO>NCT02480946</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) affect 1 percent population worldwide 40 percent patient n't respond current treatment . MBS2320 , drug test trial , represent new approach treat RA , potential reduce level inflammation also directly inhibit bone damage.The aim study test safety MBS2320 healthy volunteer , find MBS2320 level change blood dose , test safety compatibility give MBS2320 patient RA combination exist treatment , methotrexate .</brief_summary>
	<brief_title>Safety Tolerability Study MBS2320 Healthy Subjects Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>The study conduct 4 part ( part A D ) . The principal aim study obtain safety tolerability data MBS2320 administer orally single multiple dos healthy subject ( part A C ) . The effect MBS2320 pharmacokinetics ( PK ) first-line rheumatoid arthritis ( RA ) therapy , methotrexate ( MTX ) , effect MTX PK MBS2320 , also evaluate cohort consist subject RA ( Part D ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Principal Parts A , B , C. Healthy male females 18 60 year age . A body mass index ( BMI ) 18.0 30.0 kg/m2 . Female subject nonchildbearing potential postmenopausal define protocol . Female subject must pregnant . Part D Subjects otherwise healthy male female diagnosis RA 18 70 year age . Subjects BMI 18.0 30.0 kg/m2 . Female subject must pregnant . Subjects must treat , tolerate , oral subcutaneous MTX minimum 3 month prior screen entry . Principal Parts A , B , C. Male subject agree use appropriate contraception . Female subject receive HRT agree use appropriate contraception . Subjects donate blood 3 month , plasma 7 day platelets 6 week prior screen . Subjects consume permit alcohol requirement , significant history alcoholism drug/chemical abuse . Subjects unwilling abstain alcohol require . A positive urine drug screen , alcohol breath test screen first admission . Subject receive live virus vaccination within 30 day prior first dose administration . Subjects positive test tuberculosis . Additional Part D Exclusions Subjects receive medication ( except MTX ) know chronically alter drug absorption elimination process within 30 day prior first dose administration . Subjects currently take medication allow per protocol guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Osteoclastogenesis inhibitor</keyword>
	<keyword>Anti-Inflammatory Agent</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
</DOC>